In addition, the down-regulation of CXCL1 (logrank P = 0.0094), CXCL2 (logrank P = 0.0039) and CXCL3 (logrank P = 0.033), and the up-regulation of CXCL9 (logrank P = 0.0049) were significantly associated with poor overall survival in BC patients (Figures 5B–I). This evidence concerns the gene CXCL2 and breast cancer.